CLEMENTIA PHARMACEUTICALS INC (CMTA) Stock Price & Overview

NASDAQ:CMTA

26.35
-0.03 (-0.11%)
At close: Apr 17, 2019
26.05
-0.3 (-1.14%)
After Hours: 4/17/2019, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

The current stock price of CMTA is 26.35 null. Today CMTA is down by -0.11%. In the past month the price increased by 1.78%. In the past year, price increased by 49.46%.

CMTA Key Statistics

52-Week Range8.1 - 26.73
Current CMTA stock price positioned within its 52-week range.
1-Month Range25.81 - 26.73
Current CMTA stock price positioned within its 1-month range.
Market Cap
1.003B
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.59
Dividend Yield
N/A

CMTA Stock Performance

Today
-0.11%
1 Week
-0.49%
1 Month
+1.78%
3 Months
+95.04%
Longer-term
6 Months +174.48%
1 Year +49.46%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

CMTA Stock Chart

CLEMENTIA PHARMACEUTICALS INC / CMTA Daily stock chart

CMTA Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to CMTA. When comparing the yearly performance of all stocks, CMTA is one of the better performing stocks in the market, outperforming 98.07% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
CMTA Full Technical Analysis Report

CMTA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to CMTA. While CMTA has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CMTA Full Fundamental Analysis Report

CMTA Earnings

Next Earnings DateN/A
Last Earnings DateN/A
CMTA Earnings History

CMTA Forecast & Estimates


Analysts
Analysts60
Price TargetN/A
EPS Next Y79.45%
Revenue Next YearN/A
CMTA Forecast & Estimates

CMTA Financial Highlights

Over the last trailing twelve months CMTA reported a non-GAAP Earnings per Share(EPS) of -1.5899999999999999. The EPS increased by 77.59% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-58.13M
Industry RankSector Rank
PM (TTM) N/A
ROA -32.87%
ROE -35.35%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%74.86%
Sales Q2Q%N/A
EPS 1Y (TTM)77.59%
Revenue 1Y (TTM)N/A
CMTA financials

CMTA Ownership

Ownership
Inst Owners78.72%
Shares38.06M
Float19.15M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
CMTA Ownership

About CMTA

Company Profile

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company's lead product consists of palovarotene, a novel RAR' agonist, to treat fibrodysplasia ossificans progressiva, multiple osteochondroma and other diseases. Clementia Pharmaceuticals Inc. is based in Montreal, Canada.

Company Info

CLEMENTIA PHARMACEUTICALS INC

4150 ST CATHERINE STREET WEST SUITE 550

MONTREAL A8 H3Z 2Y5

CEO: Clarissa Desjardins

Phone: 514-940-3600

CLEMENTIA PHARMACEUTICALS INC / CMTA FAQ

What does CLEMENTIA PHARMACEUTICALS INC do?

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company's lead product consists of palovarotene, a novel RAR' agonist, to treat fibrodysplasia ossificans progressiva, multiple osteochondroma and other diseases. Clementia Pharmaceuticals Inc. is based in Montreal, Canada.


Can you provide the latest stock price for CLEMENTIA PHARMACEUTICALS INC?

The current stock price of CMTA is 26.35 null. The price decreased by -0.11% in the last trading session.


Does CLEMENTIA PHARMACEUTICALS INC pay dividends?

CMTA does not pay a dividend.


What is the ChartMill technical and fundamental rating of CMTA stock?

CMTA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.